We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Abbott Laboratories
Health Care · Health Care Equipment
Structural: Diversified medtech compounder with four cash-generative legs -- Medical Devices (~45% of sales, fastest grower), Diagnostics, Nutrition, Established Pharma. FreeStyle Libre is the dominant consumer CGM franchise globally (~$6B+ run-rate, mid-teens growth), competing with $DXCM.
Structural Heart (MitraClip, Navitor TAVR, Amulet LAA) is a multi-billion growth engine vs $MDT and $EW. Aging demographics + chronic-disease prevalence underwrite secular volume tailwinds.
(1) Libre attach in basal/Type-2 still early -- Medicare expansion + OTC Lingo open new pools. (2) Structural heart pipeline (Volt PFA, Aveir leadless) catches up to $BSX/$MDT. (3) Diagnostics base normalised post-COVID -- core lab + molecular grow off a clean comp.
(4) Dividend Aristocrat (50+ yrs), buybacks layered, balance sheet investment-grade. (5) EM nutrition + EPD give non-correlated growth vs US-centric peers.
(1) Libre faces $DXCM G7 + Stelo OTC competition; ASP pressure as category commoditises. (2) Nutrition segment still carries litigation tail from the 2022 infant-formula recall (NEC cases). (3) FX + EM volatility drag reported growth. (4) Pharma pipeline thin vs $LLY/$NVO; no GLP-1 leg.
(5) Multiple already prices in steady mid-single-digit organic + margin expansion -- limited rerating headroom absent device acceleration.
No major news in the last 7 days for ABT - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.